A day after the Supreme Court rapped the Health Ministry for allowing Indians to be used as "guinea pigs" in the conduct of drug trials, top sources told PTI that the rules meant to monitor clinical trials under the Drugs and Cosmetics Act would be notified within this month.
After notifying these rules which will lay down guidelines for pharma companies engaging in drug trials in India, government will further amend the Drugs and Cosmetics Act to make lapses by pharma MNCs a punishable offence under law, they said.
Waking up to regulate the clinical trial sector, the Ministry under the new rules will for the first time put specific responsibility on investigators and sponsors of drug trials -- making it mandatory for them to address issue of medical management of subjects involved in trials in case of serious adverse events such as death.
The new rules will also prescribe a formula providing for higher compensation in case of serious adverse event like death during the trials and fix a minimum compensation amount. So far, drug companies have been getting away with arbitrary payments sometimes as less as Rs 50,000 in case of a life lost during a trial.
Health Ministry officials finalised the draft rules following a series of meetings yesterday after the apex court came down heavily on the Ministry for sending a junior officer to file an affidavit in such a serious health matter.
Asking for the personal presence of Health Secretary in the matter, the Supreme Court gave the Ministry four weeks to respond to a PIL in the matter. (More)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
